NASDAQ:SIBN - SI-BONE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.00
  • Forecasted Upside: 72.66 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$21.43
▲ +0.27 (1.28%)

This chart shows the closing price for SIBN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SI-BONE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SIBN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SIBN

Analyst Price Target is $37.00
▲ +72.66% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for SI-BONE in the last 3 months. The average price target is $37.00, with a high forecast of $40.00 and a low forecast of $32.00. The average price target represents a 72.66% upside from the last price of $21.43.

This chart shows the closing price for SIBN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in SI-BONE. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2021Needham & Company LLCLower Price TargetBuy$37.00 ➝ $32.00High
11/9/2021JMP SecuritiesLower Price TargetMarket Outperform$42.00 ➝ $36.00High
9/30/2021Truist SecuritiesLower Price TargetBuy$43.00 ➝ $37.00High
9/30/2021TruistLower Price TargetBuy$43.00 ➝ $37.00High
8/3/2021Morgan StanleyLower Price TargetOverweight$41.00 ➝ $40.00High
8/3/2021Needham & Company LLCReiterated RatingBuy$42.00 ➝ $37.00High
6/8/2021CitigroupInitiated CoverageBuyMedium
5/4/2021Truist SecuritiesBoost Price Target$35.00 ➝ $43.00Medium
5/4/2021TruistBoost Price Target$35.00 ➝ $43.00High
5/4/2021Canaccord GenuityBoost Price TargetBuy$39.00 ➝ $40.00High
5/4/2021Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $42.00High
5/4/2021Morgan StanleyBoost Price TargetOverweight$38.00 ➝ $41.00High
4/19/2021Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $38.00High
3/9/2021Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $35.00High
3/9/2021Needham & Company LLCLower Price TargetBuy$35.00 ➝ $34.00High
2/1/2021Needham & Company LLCReiterated RatingBuy$27.00Low
1/8/2021JMP SecuritiesBoost Price TargetOutperform$27.00 ➝ $35.00Medium
12/17/2020Canaccord GenuityBoost Price TargetBuy$30.00 ➝ $34.00High
12/16/2020Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $35.00N/A
12/15/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $32.00Low
9/30/2020JMP SecuritiesBoost Price TargetOutperform$22.00 ➝ $27.00High
8/4/2020Morgan StanleyBoost Price TargetOverweight$20.00 ➝ $25.00High
8/4/2020Canaccord GenuityReiterated RatingBuy$24.00High
8/4/2020Needham & Company LLCBoost Price TargetBuy$22.00 ➝ $24.00High
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$25.00Low
6/8/2020Cantor FitzgeraldReiterated RatingOverweightMedium
5/29/2020Needham & Company LLCReiterated RatingBuy$22.00High
5/5/2020JMP SecuritiesLower Price TargetMarket Outperform$27.00 ➝ $22.00Medium
5/5/2020Morgan StanleyBoost Price TargetOverweight$18.00 ➝ $20.00High
5/5/2020Needham & Company LLCLower Price TargetBuy$27.00 ➝ $22.00High
3/27/2020Morgan StanleyLower Price TargetOverweight$24.00 ➝ $18.00High
2/19/2020Needham & Company LLCInitiated CoverageBuy$27.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$27.00Low
12/17/2019Cantor FitzgeraldInitiated CoverageOverweight$27.00Low
11/12/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$23.00Low
11/12/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$24.00Low
11/12/2018Canaccord GenuityInitiated CoverageBuy ➝ Buy$25.00Low
11/12/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$27.00Low
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 5 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/9/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/8/2021

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
SI-BONE logo
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.
Read More

Today's Range

Now: $21.43
Low: $20.84
High: $21.68

50 Day Range

MA: $21.99
Low: $18.75
High: $24.80

52 Week Range

Now: $21.43
Low: $18.48
High: $37.21

Volume

208,448 shs

Average Volume

326,297 shs

Market Capitalization

$717.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of SI-BONE?

The following sell-side analysts have issued stock ratings on SI-BONE in the last year: Canaccord Genuity, Citigroup Inc., JMP Securities, Morgan Stanley, Needham & Company LLC, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for SIBN.

What is the current price target for SI-BONE?

6 Wall Street analysts have set twelve-month price targets for SI-BONE in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 74.9%. Canaccord Genuity has the highest price target set, predicting SIBN will reach $40.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $32.00 for SI-BONE in the next year.
View the latest price targets for SIBN.

What is the current consensus analyst rating for SI-BONE?

SI-BONE currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SIBN will outperform the market and that investors should add to their positions of SI-BONE.
View the latest ratings for SIBN.

What other companies compete with SI-BONE?

How do I contact SI-BONE's investor relations team?

SI-BONE's physical mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company's listed phone number is (408) 207-0700 and its investor relations email address is [email protected] The official website for SI-BONE is www.si-bone.com.